Literature DB >> 10098765

Tissue inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanced stages of thyroid carcinoma.

Y Shi1, R S Parhar, M Zou, M M Hammami, M Akhtar, Z P Lum, N R Farid, S T Al-Sedairy, M C Paterson.   

Abstract

Tumour cell invasion and metastasis is a multistep process that involves the degradation of extracellular matrix proteins by matrix metalloproteinases (MMPs). Tissue inhibitors of metalloproteinases (TIMPs) act as negative regulators of MMPs and thus prevent tumour cell invasion and metastasis by preserving extracellular matrix (ECM) integrity. In the present study we examined the expression of one member of TIMPs, TIMP-1, in 39 thyroid tumour specimens and two thyroid carcinoma cell lines (NPA and SW579). We also investigated the effect of high TIMP-1 expression on the invasive potential of NPA cells. Northern blot analysis showed that TIMP-1 mRNA levels correlated directly with tumour aggressiveness: the highest number of TIMP-1 transcripts was found in stages III and IV vs benign goitre (P < 0.0001). However, TIMP-1 expression was not increased in NPA and SW579 cells, both of which are derived from poorly differentiated thyroid tumours. Immunohistochemical study showed strong TIMP-1 staining in the stroma cells of advanced stages of carcinomas. Overexpression of TIMP-1 by gene transfer resulted in a significant suppression of the malignant phenotype of NPA cells as judged by an in vitro tumour invasion assay. These results suggest that high levels of TIMP-1 transcripts in advanced stages of thyroid carcinoma likely come from stroma rather than thyroid cancer cells, and TIMP-1 may function as a thyroid tumour invasion/metastasis suppressor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098765      PMCID: PMC2362222          DOI: 10.1038/sj.bjc.6690198

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

Review 1.  Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; P S Steeg; W G Stetler-Stevenson
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

2.  A rapid in vitro assay for quantitating the invasive potential of tumor cells.

Authors:  A Albini; Y Iwamoto; H K Kleinman; G R Martin; S A Aaronson; J M Kozlowski; R N McEwan
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  Metalloproteinases and cancer invasion and metastasis.

Authors:  G Murphy; J J Reynolds; R M Hembry
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

5.  Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials.

Authors:  M Nakajima; D R Welch; P N Belloni; G L Nicolson
Journal:  Cancer Res       Date:  1987-09-15       Impact factor: 12.701

6.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

7.  A simple quantitative assay for studying the invasive potential of high and low human metastatic variants.

Authors:  M J Hendrix; E A Seftor; R E Seftor; I J Fidler
Journal:  Cancer Lett       Date:  1987-12       Impact factor: 8.679

8.  Primary structure and cDNA cloning of human fibroblast collagenase inhibitor.

Authors:  D F Carmichael; A Sommer; R C Thompson; D C Anderson; C G Smith; H G Welgus; G P Stricklin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

9.  Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2.

Authors:  G I Goldberg; B L Marmer; G A Grant; A Z Eisen; S Wilhelm; C S He
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

10.  Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases.

Authors:  Z S Zeng; A M Cohen; Z F Zhang; W Stetler-Stevenson; J G Guillem
Journal:  Clin Cancer Res       Date:  1995-08       Impact factor: 12.531

View more
  6 in total

Review 1.  Angiogenesis inhibitors.

Authors:  T R Tennant; C W Rinker-Schaeffer; W M Stadler
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

2.  Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents.

Authors:  A Patel; A M Straight; H Mann; E Duffy; C Fenton; C Dinauer; R M Tuttle; G L Francis
Journal:  J Endocrinol Invest       Date:  2002-05       Impact factor: 4.256

3.  In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior.

Authors:  Marius I Ilie; Sandra Lassalle; Elodie Long-Mira; Véronique Hofman; Joséphine Zangari; Gilles Bénaim; Alexandre Bozec; Nicolas Guevara; Juliette Haudebourg; Isabelle Birtwisle-Peyrottes; José Santini; Patrick Brest; Paul Hofman
Journal:  Virchows Arch       Date:  2013-07-27       Impact factor: 4.064

4.  S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma.

Authors:  M Zou; R S Al-Baradie; H Al-Hindi; N R Farid; Y Shi
Journal:  Br J Cancer       Date:  2005-11-28       Impact factor: 7.640

5.  Serum biomarkers of papillary thyroid cancer.

Authors:  Fawaz M Makki; S Mark Taylor; Ali Shahnavaz; Andrew Leslie; Jeffrey Gallant; Susan Douglas; Evelyn Teh; Jonathan Trites; Martin Bullock; Karen Inglis; Devanand M Pinto; Robert D Hart
Journal:  J Otolaryngol Head Neck Surg       Date:  2013-02-07

6.  Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses.

Authors:  M Elise R Graham; Robert D Hart; Susan Douglas; Fawaz M Makki; Devanand Pinto; Angela L Butler; Martin Bullock; Matthew H Rigby; Jonathan R B Trites; S Mark Taylor; Rama Singh
Journal:  J Otolaryngol Head Neck Surg       Date:  2015-09-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.